Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide

Table 5 Cytogenetic categories and response to therapy in the cohort of LEN patients

A. All patient who received LEN for more than 3 months (N = 38)
	Normal cytogenetic group	Abnormal cytogenetic group	p value
Categorized by MC only	64%	33%	0.07
Categorized by MC/FISH/SNP-A	64%	54%	0.4
B. Monotherapy (LEN only) patients (N = 27)
	Normal cytogenetic group	Abnormal cytogenetic group	p value
Categorized by MC	60%	17%	0.08
only
Categorized by MC/FISH/SNP-A	64%	44%	0.27
C. Patients with combination therapy of AZA + LEN (N = 11)
	Normal cytogenetic group	Abnormal cytogenetic group	p value
Categorized by MC only	75%	67%	0.85
Categorized by MC/FISH/SNP-A	67%	75%	0.85

LEN lenalidomide; MC metaphase cytogenetics; FISH fluorescence in situ hybridization; SNP-A single nucleotide polymorphism array karyotyping; AZA azacitidine.

ISSN: 1756-8722